Deka Biosciences, Inc

Deka Biosciences, Inc company information, Employees & Contact Information

Deka Biosciences, Inc., is an early-stage biotechnology company focused on generating the next generation targeted cytokine therapies to treat cancer and inflammatory diseases. Deka is developing the dual cytokine, (DiakineTM) platform. Diakines are comprised of optimized, stimulatory, or suppressive disease specific IL-10 variants coupled to other stimulatory or suppressive cytokines via a T1/2 life extending tissue targeting, non-immunogenic scFv technology.

Company Details

Employees
20
Address
20271 Goldenrod Lane,
Phone
6502670338
Email
mu****@****ces.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Germantown, MD
Looking for a particular Deka Biosciences, Inc employee's phone or email?

Deka Biosciences, Inc Questions

News

Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity - ScienceDirect.com

Coupling IL-2 with IL-10 to mitigate toxicity and enhance antitumor immunity ScienceDirect.com

Deka Biosciences Raises USD 20 Million in Series A Financing - PR Newswire

Deka Biosciences Raises USD 20 Million in Series A Financing PR Newswire

Phase 1 Trial of DK210 Begins Dosing Patients With EGFR+ Solid Tumors - Targeted Oncology

Phase 1 Trial of DK210 Begins Dosing Patients With EGFR+ Solid Tumors Targeted Oncology

Deka Biosciences secures $20m to advance product pipeline - Pharmaceutical Technology

Deka Biosciences secures $20m to advance product pipeline Pharmaceutical Technology

Deka Biosciences Breaks Ground on New Facility in Germantown - The MoCo Show -

Deka Biosciences Breaks Ground on New Facility in Germantown The MoCo Show -

Deka Biosciences: $20 Million Secured To Maximize Patient Benefits Through Improved Pharmacokinetics - Pulse 2.0

Deka Biosciences: $20 Million Secured To Maximize Patient Benefits Through Improved Pharmacokinetics Pulse 2.0

Deka Biosciences Closes USD $20 Million Series B2 Financing Led by MPM BioImpact - PR Newswire

Deka Biosciences Closes USD $20 Million Series B2 Financing Led by MPM BioImpact PR Newswire

Deka Biosciences Closes USD $20M Series B2 Financing - FinSMEs

Deka Biosciences Closes USD $20M Series B2 Financing FinSMEs

Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors - PR Newswire

Deka Biosciences Adds Industry Veterans to its Executive Leadership Team and Board of Directors PR Newswire

Top Deka Biosciences, Inc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant